STOCK TITAN

Passage Bio misses Nasdaq equity minimum with $50K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Passage Bio, Inc. (PASG) received a Nasdaq notice stating it did not meet the $2,500,000 stockholders’ equity minimum for continued listing. In its quarterly report for the quarter ended September 30, 2026, the company reported stockholders’ equity of $50,000; as of November 12, 2026, it also did not meet the alternative tests based on market value of listed securities or net income from continuing operations. The notice has no immediate effect on trading: PASG common stock will continue to trade on the Nasdaq Capital Market.

Passage Bio expects to complete its previously announced mergers with Remix Therapeutics after the remaining closing conditions are satisfied or waived, including approval to list the combined company’s common stock on Nasdaq. After closing, Passage Bio expects to change its name to Remix Therapeutics, Inc., and its shares are expected to trade under RMTX. The company believes completion of the mergers and related transactions will restore compliance with the minimum-equity requirement. If the mergers are not completed within the period under Nasdaq rules, it intends to submit a plan to regain compliance.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Major pointStockholders’ equity was $50,000, below Nasdaq’s $2,500,000 continued-listing minimum.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Stockholders’ equity $50,000 Reported in the quarterly report for the quarter ended September 30, 2026.
Nasdaq continued-listing minimum $2,500,000 in stockholders’ equity Minimum required by Nasdaq Listing Rule 5550(b)(1).
Nasdaq Listing Rule 5550(b)(1) regulatory
"did not satisfy Nasdaq Listing Rule 5550(b)(1)"
stockholders’ equity financial
"minimum of $2,500,000 in stockholders’ equity"
Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.
market value of listed securities regulatory
"alternatives of market value of listed securities"
Market value of listed securities is the market value of the shares a company has listed on an exchange, calculated as the closing bid price multiplied by the number of listed shares. Exchanges use it as a continued-listing standard, so a company that stays under the required minimum receives a deficiency notice and is given a set period to recover before facing delisting.
net income from continuing operations financial
"net income from continuing operations"
Net income from continuing operations is the profit a company earns from its ongoing, day-to-day business after paying costs, interest and taxes, excluding results from businesses it has sold or closed and one-time gains or losses. Investors care because it shows the company's recurring earning power—like comparing a regular paycheck to a one-off bonus—and gives a clearer picture of sustainable profits used to value the business and judge management performance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did PASG receive a Nasdaq listing notice?

Nasdaq notified Passage Bio that it did not satisfy the continued-listing equity standard, which requires at least $2,500,000 in stockholders’ equity. Passage Bio reported $50,000 for the quarter ended September 30, 2026, and did not meet the other listed alternatives as of November 12, 2026.

Will PASG stock immediately stop trading on Nasdaq?

No, PASG common stock will continue trading on the Nasdaq Capital Market; the notice has no immediate effect on the listing.

What will PASG do if the Remix mergers are not completed within Nasdaq’s period?

Passage Bio intends to submit a plan to regain compliance if the mergers are not completed within the period provided under Nasdaq rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 


FORM 8-K
 


CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 12, 2026
 


PASSAGE BIO, INC.
(Exact name of registrant as specified in its charter)


 
Delaware
001-39231
82-2729751
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)

Address Not Applicable1

ZIP Code Not Applicable
(Address of principal executive offices)

(Zip Code)
 
(267) 866-0311
(Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report.)
 

Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)
 
☐
Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))
 
☐
Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share
 
PASG
 
The Nasdaq Stock Market LLC
(Nasdaq Capital Market)
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b‑2 of the Securities Exchange Act of 1934 (§240.12b‑2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


1 We are a remote-only company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to our principal executive offices may be directed to P.O. Box 7, Hopewell, New Jersey 08525.



Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 12, 2026, Passage Bio, Inc. (“Passage Bio” or the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying it that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, Passage Bio reported stockholders’ equity of $50,000, and, as of November 12, 2026, Passage Bio did not meet the alternatives of market value of listed securities or net income from continuing operations. As a result, Passage Bio did not satisfy Nasdaq Listing Rule 5550(b)(1) as of the date of the Letter.
 
Passage Bio expects to complete its previously announced mergers with Remix Therapeutics, Inc., a Delaware corporation (“Remix”), in accordance with the terms of the Amended and Restated Agreement and Plan of Merger, dated September 2, 2026, as amended on October 5, 2026, by and among Passage Bio, Peregrine Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Passage Bio (“Merger Sub”), Peregrine Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Passage Bio (“Merger Sub II”), and Remix, providing for the merger of Merger Sub with and into Remix, with Remix surviving as a wholly owned subsidiary of Passage Bio (the “First Merger”), and the subsequent merger of the surviving entity of the First Merger with and into Merger Sub II, with Merger Sub II surviving as a wholly owned subsidiary of Passage Bio (together with the First Merger, the “Mergers”). The Mergers are expected to close as promptly as practicable following the satisfaction or waiver of the remaining closing conditions, including approval of the listing of the combined company’s common stock on Nasdaq. Upon the closing, Passage Bio expects to change its name from “Passage Bio, Inc.” to “Remix Therapeutics, Inc.”

The Company believes that, upon the completion of the Mergers and the transactions contemplated therewith, it will have regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement. For more information related to the Mergers and the transactions contemplated therewith, please see the Company’s registration statement on Form S-4, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 21, 2026, most recently amended on October 8, 2026 and declared effective by the SEC on October 9, 2026, including the documents and filings incorporated by reference therein.

The Letter has no immediate effect on the listing of the Company’s common stock, which will continue to trade on the Nasdaq Capital Market. Following the closing of the Mergers, the Company’s common stock is expected to begin trading on Nasdaq under the symbol “RMTX.” If the Mergers are not completed within the period provided under the Nasdaq Listing Rules, the Company intends to submit a plan to regain compliance.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected timing of the completion of the Mergers, the expected change of the Company’s name and trading symbol, and the Company’s ability to regain compliance with Nasdaq Listing Rule 5550(b)(1). These statements are subject to risks and uncertainties, including the risk that the conditions to the closing of the Mergers, including approval of the listing of the combined company’s common stock on Nasdaq, are not satisfied on the anticipated timeline or at all, and the other risks described in the Company’s filings with the SEC, including the registration statement on Form S-4 referenced above and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Actual results may differ materially from those indicated by these forward-looking statements. The Company undertakes no obligation to update any forward-looking statement, except as required by law.
 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 18, 2026
PASSAGE BIO, INC.
 
By:
 /s/ Kathleen Borthwick
 
Name:
 Kathleen Borthwick
 
Title:
 Chief Financial Officer



Filing Exhibits & Attachments

3 documents

Keep reading